Literature DB >> 16697805

Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.

Stefania Mariani1, Luisa Salvatori, Sabrina Basciani, Mario Arizzi, Giorgio Franco, Elisa Petrangeli, Giovanni Spera, Lucio Gnessi.   

Abstract

PURPOSE: FSH, identified as an endogenous product of the prostate, is a glycoprotein with proliferative activity. Increasing evidence of autocrine/paracrine activities of gonadotropins at extragonadal sites led us to investigate the gene expression and cellular localization of FSH-R in normal and diseased human prostates.
MATERIALS AND METHODS: Prostate specimens, including normal gland, BPH, PCa and human androgen refractory (PC3) and androgen dependent (LNCaP) prostate cancer cell lines (European Collection of Cell Cultures, Salisbury, United Kingdom), were analyzed for FSH-R expression by semiquantitative and real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry. We also evaluated cyclic adenosine monophosphate production by cultured PC3 and LNCaP stimulated with human FSH.
RESULTS: Little FSH-R expression was seen in 9 of 13 normal and 8 of 15 BPH specimens. Of 30 PCa samples 21 were FSH-R positive with generally higher expression compared to normal prostate and BPH samples. Real-time reverse transcriptase-polymerase chain reaction of matched normal/tumor pairs confirmed higher FSH-R mRNA expression in PCa. PC3 cells expressed FSH-R, while LNCaP cells were FSH-R negative. FSH-R protein was mainly localized in the glandular epithelium and in some stromal cells in normal prostate, BPH and PCa specimens. PC3 cells expressed FSH-R protein and their treatment with FSH induced a significant increase in cyclic adenosine monophosphate production.
CONCLUSIONS: These results indicate that a subset of PCa expresses FSH-R mRNA and protein at levels higher than those of normal and hyperplastic tissues that express FSH-R. This suggests that FSH might contribute to some cases of PCa via a receptor mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697805     DOI: 10.1016/S0022-5347(06)00273-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

Review 1.  Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?

Authors:  Konstantinos Papadimitriou; Panteleimon Kountourakis; Anastasia E Kottorou; Anna G Antonacopoulou; Christian Rolfo; Marc Peeters; Haralabos P Kalofonos
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

2.  Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumors.

Authors:  C Sardella; D Russo; F Raggi; M Lombardi; C Urbani; S Brogioni; U Boggi; N Funel; B Chifenti; D Campani; G Fanelli; P Marchetti; F Basolo; M T Locci; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2012-06-25       Impact factor: 4.256

3.  Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.

Authors:  Kazuhisa Hagiwara; Takuya Koie; Chikara Ohyama; Hayato Yamamoto; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Yuki Tobisawa; Tohru Yoneyama
Journal:  Int Urol Nephrol       Date:  2017-02-17       Impact factor: 2.370

4.  Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.

Authors:  Alfredo Perales-Puchalt; Krzysztof Wojtak; Elizabeth K Duperret; Xue Yang; Anna M Slager; Jian Yan; Kar Muthumani; Luis J Montaner; David B Weiner
Journal:  Mol Ther       Date:  2018-12-13       Impact factor: 11.454

5.  Antagonizing GnRH receptors: A temporary ADT salvage maneuver for prostate cancer patients experiencing PSA failure with GnRH agonist.

Authors:  Jehonathan Pinthus
Journal:  Can Urol Assoc J       Date:  2020-02       Impact factor: 1.862

Review 6.  Current concepts of follicle-stimulating hormone receptor gene regulation.

Authors:  Jitu W George; Elizabeth A Dille; Leslie L Heckert
Journal:  Biol Reprod       Date:  2010-08-25       Impact factor: 4.285

7.  Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.

Authors:  Yuping Xu; Donghui Pan; Chen Zhu; Qing Xu; Lizhen Wang; Fei Chen; Runlin Yang; Shineng Luo; Min Yang; Yongjun Yan
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

8.  Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.

Authors:  Peter B Østergren; Caroline Kistorp; Mikkel Fode; James Henderson; Finn N Bennedbæk; Jens Faber; Jens Sønksen
Journal:  J Urol       Date:  2016-12-09       Impact factor: 7.450

9.  Experience with degarelix in the treatment of prostate cancer.

Authors:  Neal D Shore
Journal:  Ther Adv Urol       Date:  2013-02

10.  Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.

Authors:  Peter Iversen; Jan-Erik Damber; Anders Malmberg; Bo-Eric Persson; Laurence Klotz
Journal:  Ther Adv Urol       Date:  2015-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.